[go: up one dir, main page]

MX2019012285A - Metodos de tratamiento de encefalopatias del desarrollo. - Google Patents

Metodos de tratamiento de encefalopatias del desarrollo.

Info

Publication number
MX2019012285A
MX2019012285A MX2019012285A MX2019012285A MX2019012285A MX 2019012285 A MX2019012285 A MX 2019012285A MX 2019012285 A MX2019012285 A MX 2019012285A MX 2019012285 A MX2019012285 A MX 2019012285A MX 2019012285 A MX2019012285 A MX 2019012285A
Authority
MX
Mexico
Prior art keywords
methods
treating developmental
encephalopathies
developmental encephalopathies
ketamine
Prior art date
Application number
MX2019012285A
Other languages
English (en)
Inventor
Matthew During
Original Assignee
Ovid Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ovid Therapeutics Inc filed Critical Ovid Therapeutics Inc
Publication of MX2019012285A publication Critical patent/MX2019012285A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Inorganic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Otolaryngology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Se proporcionan métodos para el tratamiento contra encefalopatías del desarrollo mediante la administración de composiciones que incluyen ketamina, norketamina, u otros derivados de Ia ketamina, o una sal farmacéuticamente aceptable de cualquiera de las anteriores. Los métodos y composiciones pueden utilizarse para el tratamiento contra afecciones tales como el síndrome de Dravet.
MX2019012285A 2017-04-13 2018-04-12 Metodos de tratamiento de encefalopatias del desarrollo. MX2019012285A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762485211P 2017-04-13 2017-04-13
US201762501885P 2017-05-05 2017-05-05
PCT/US2018/027276 WO2018191482A2 (en) 2017-04-13 2018-04-12 Methods of treating developmental encephalopathies

Publications (1)

Publication Number Publication Date
MX2019012285A true MX2019012285A (es) 2020-11-06

Family

ID=63791354

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019012285A MX2019012285A (es) 2017-04-13 2018-04-12 Metodos de tratamiento de encefalopatias del desarrollo.

Country Status (5)

Country Link
US (1) US10765646B2 (es)
EP (1) EP3609481A4 (es)
CA (1) CA3059775A1 (es)
MX (1) MX2019012285A (es)
WO (1) WO2018191482A2 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2014250756B2 (en) 2013-04-12 2019-03-07 Icahn School Of Medicine At Mount Sinai Method for treating post-traumatic stress disorder
CN108603230A (zh) 2015-10-09 2018-09-28 南安普敦大学 基因表达的调节与蛋白质表达失调的筛选
WO2017106377A1 (en) 2015-12-14 2017-06-22 Cold Spring Harbor Laboratory Antisense oligomers for treatment of autosomal dominant mental retardation-5 and dravet syndrome
WO2018027037A2 (en) 2016-08-03 2018-02-08 University Of South Florida Reelin compositions for treatment of neurological disorders
GB2594767B (en) 2017-08-25 2022-06-22 Stoke Therapeutics Inc Antisense oligomers for treatment of conditions and diseases
CA3099280A1 (en) 2018-05-04 2019-11-07 Stoke Therapeutics, Inc. Methods and compositions for treatment of cholesteryl ester storage disease
US20220062200A1 (en) 2019-05-07 2022-03-03 Clexio Biosciences Ltd. Abuse-deterrent dosage forms containing esketamine
US11324707B2 (en) 2019-05-07 2022-05-10 Clexio Biosciences Ltd. Abuse-deterrent dosage forms containing esketamine
KR20230022409A (ko) 2020-05-11 2023-02-15 스톡 테라퓨틱스, 인크. 병태 및 질환의 치료를 위한 opa1 안티센스 올리고머
JP2024520510A (ja) * 2021-05-28 2024-05-24 アイカーン スクール オブ メディスン アット マウント サイナイ 薬物抵抗性てんかんを処置する方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120021943A1 (en) * 2009-02-11 2012-01-26 Cgc Genetics/Centro De Genetica Clinica, Sa Multiple genetic disease diagnostic panels by one single test using microarray technology
US20140222473A1 (en) * 2013-02-01 2014-08-07 Pareshkumar Patel Method and system of direct bidding for a travel-related service via an internet-based travel system
LT2968221T (lt) * 2013-03-15 2019-07-25 Janssen Pharmaceutica Nv S-ketamino hidrochlorido farmacinė kompozicija
US9549909B2 (en) * 2013-05-03 2017-01-24 The Katholieke Universiteit Leuven Method for the treatment of dravet syndrome
EP3960162A1 (en) * 2013-08-26 2022-03-02 Amorsa Therapeutics, Inc. Single-layer oral dose of neuro-attenuating ketamine
HUE066468T2 (hu) 2014-11-04 2024-08-28 Acadia Pharm Inc Idegnyugtató norketamin vegyületek és eljárások
JP6541614B2 (ja) 2015-08-07 2019-07-10 株式会社クボタ 作業車

Also Published As

Publication number Publication date
WO2018191482A2 (en) 2018-10-18
CA3059775A1 (en) 2018-10-18
US20180296501A1 (en) 2018-10-18
US10765646B2 (en) 2020-09-08
EP3609481A2 (en) 2020-02-19
EP3609481A4 (en) 2021-05-26
WO2018191482A3 (en) 2020-04-02

Similar Documents

Publication Publication Date Title
MX2019012285A (es) Metodos de tratamiento de encefalopatias del desarrollo.
SA520411125B1 (ar) Nlrp مركبات وتركيبات لمعالجة حالات مرضية مرتبطة بنشاط
PH12020550901A1 (en) Macrocyclic compounds for treating disease
WO2015023976A3 (en) Selective grp94 inhibitors and uses thereof
MX2015011898A (es) Compuestos de pirazolo y usos de los mismos.
EA201891910A1 (ru) Гетероарильные ингибиторы pad4
AU2015336400A8 (en) Novel Aminoalkyl benzothiazepine Derivatives And Uses Thereof
EA201691194A1 (ru) Стимуляторы ргц
MX2018002906A (es) Metodos de tratamiento de trastornos del desarrollo con pipradrol.
JOP20160092B1 (ar) علاج البيتا ثلاسيميا باستخدام مصطبة لجائنية
SG10201804868PA (en) Compounds for the inhibition of indoleamine-2,3-dioxygenase
WO2014113429A3 (en) Substituted pyrrolopyrimidine compounds, compositions thereof, and methods of treatment therewith
MY186547A (en) 4?-fluoro-2?-methyl substituted nucleoside derivatives
WO2015184257A3 (en) Small molecule transcription modulators of bromodomains
EA201891347A1 (ru) Аза-бензимидазольные ингибиторы pad4
UA116053C2 (uk) Застосування похідних бензоімідазолу-проліну
UA115357C2 (uk) Похідні піридин-4-ілу
EP4292652A3 (en) Compounds for the treatment of glycogen storage disorders
UY37250A (es) Derivados macrocíclicos de indol
PH12016502002B1 (en) Novel bacteriophage and composition comprising same
WO2016069477A3 (en) A method of treating cancer that overexpresses topbp1
AU2018253600A1 (en) Dosage forms and therapeutic uses of l-4-chlorokynurenine
EA201691566A1 (ru) Применение производных пиридазина для предупреждения или лечения атаксического синдрома
NZ757526A (en) Naphthoquinones, their derivatives and uses thereof in methods for the treatment of mitochondrial dysfunction
TN2019000032A1 (en) Pharmaceutical compositions and uses directed to lysosomal storage disorders